Choline PET for monitoring early tumor response to photodynamic therapy

Baowei Fei, Hesheng Wang, Chunying Wu, Song Mao Chiu

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Photodynamic therapy (PDT) is a relatively new therapy that has shown promise for treating various cancers in both preclinical and clinical studies. The present study evaluated the potential use of PET with radiolabeled choline to monitor early tumor response to PDT in animal models. Methods: Two human prostate cancer models (PC-3 and CWR22) were studied in athymic nude mice. A second-generation photosensitizer, phthalocyanine 4 (Pc 4), was delivered to each animal by a tail vein injection 48 h before laser illumination. Small-animal PET images with 11C-choline were acquired before PDT and at 1, 24, and 48 h after PDT. Time-activity curves of 11C-choline uptake were analyzed before and after PDT. The percentage of the injected dose per gram of tissue was quantified for both treated and control tumors at each time point. In addition, Pc 4-PDT was performed in cell cultures. Cell viability and 11C-choline uptake in PDT-treated and control cells were measured. Results: For treated tumors, normalized 11C-choline uptake decreased significantly 24 and 48 h after PDT, compared with the same tumors before PDT (P < 0.001). For the control tumors, normalized 11C-choline uptake increased significantly. For mice with CWR22 tumors, the prostate-specific antigen level decreased 24 and 48 h after PDT. Pc 4-PDT in cell culture showed that the treated tumor cells, compared with the control cells, had less than 50% 11C-choline activity at 5, 30, and 45 min after PDT, whereas the cell viability test showed that the treated cells were viable longer than 7 h after PDT. Conclusion: PET with 11C- choline is sensitive for detecting early changes associated with Pc 4-PDT in mouse models of human prostate cancer. Choline PET has the potential to determine whether a PDT-treated tumor responds to treatment within 48 h after therapy.

Original languageEnglish (US)
Pages (from-to)130-138
Number of pages9
JournalJournal of Nuclear Medicine
Volume51
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Photochemotherapy
Choline
Neoplasms
Nude Mice
Prostatic Neoplasms
Cell Survival
Cell Culture Techniques
Photosensitizing Agents
Prostate-Specific Antigen
Lighting
Tail
Veins

Keywords

  • Choline molecular imaging
  • Photodynamic therapy (PDT)
  • Prostate cancer
  • Small-animal PET
  • Tumor response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Choline PET for monitoring early tumor response to photodynamic therapy. / Fei, Baowei; Wang, Hesheng; Wu, Chunying; Chiu, Song Mao.

In: Journal of Nuclear Medicine, Vol. 51, No. 1, 01.01.2010, p. 130-138.

Research output: Contribution to journalArticle

Fei, Baowei ; Wang, Hesheng ; Wu, Chunying ; Chiu, Song Mao. / Choline PET for monitoring early tumor response to photodynamic therapy. In: Journal of Nuclear Medicine. 2010 ; Vol. 51, No. 1. pp. 130-138.
@article{7cce1563782841268b3de72034646226,
title = "Choline PET for monitoring early tumor response to photodynamic therapy",
abstract = "Photodynamic therapy (PDT) is a relatively new therapy that has shown promise for treating various cancers in both preclinical and clinical studies. The present study evaluated the potential use of PET with radiolabeled choline to monitor early tumor response to PDT in animal models. Methods: Two human prostate cancer models (PC-3 and CWR22) were studied in athymic nude mice. A second-generation photosensitizer, phthalocyanine 4 (Pc 4), was delivered to each animal by a tail vein injection 48 h before laser illumination. Small-animal PET images with 11C-choline were acquired before PDT and at 1, 24, and 48 h after PDT. Time-activity curves of 11C-choline uptake were analyzed before and after PDT. The percentage of the injected dose per gram of tissue was quantified for both treated and control tumors at each time point. In addition, Pc 4-PDT was performed in cell cultures. Cell viability and 11C-choline uptake in PDT-treated and control cells were measured. Results: For treated tumors, normalized 11C-choline uptake decreased significantly 24 and 48 h after PDT, compared with the same tumors before PDT (P < 0.001). For the control tumors, normalized 11C-choline uptake increased significantly. For mice with CWR22 tumors, the prostate-specific antigen level decreased 24 and 48 h after PDT. Pc 4-PDT in cell culture showed that the treated tumor cells, compared with the control cells, had less than 50{\%} 11C-choline activity at 5, 30, and 45 min after PDT, whereas the cell viability test showed that the treated cells were viable longer than 7 h after PDT. Conclusion: PET with 11C- choline is sensitive for detecting early changes associated with Pc 4-PDT in mouse models of human prostate cancer. Choline PET has the potential to determine whether a PDT-treated tumor responds to treatment within 48 h after therapy.",
keywords = "Choline molecular imaging, Photodynamic therapy (PDT), Prostate cancer, Small-animal PET, Tumor response",
author = "Baowei Fei and Hesheng Wang and Chunying Wu and Chiu, {Song Mao}",
year = "2010",
month = "1",
day = "1",
doi = "10.2967/jnumed.109.067579",
language = "English (US)",
volume = "51",
pages = "130--138",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "1",

}

TY - JOUR

T1 - Choline PET for monitoring early tumor response to photodynamic therapy

AU - Fei, Baowei

AU - Wang, Hesheng

AU - Wu, Chunying

AU - Chiu, Song Mao

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Photodynamic therapy (PDT) is a relatively new therapy that has shown promise for treating various cancers in both preclinical and clinical studies. The present study evaluated the potential use of PET with radiolabeled choline to monitor early tumor response to PDT in animal models. Methods: Two human prostate cancer models (PC-3 and CWR22) were studied in athymic nude mice. A second-generation photosensitizer, phthalocyanine 4 (Pc 4), was delivered to each animal by a tail vein injection 48 h before laser illumination. Small-animal PET images with 11C-choline were acquired before PDT and at 1, 24, and 48 h after PDT. Time-activity curves of 11C-choline uptake were analyzed before and after PDT. The percentage of the injected dose per gram of tissue was quantified for both treated and control tumors at each time point. In addition, Pc 4-PDT was performed in cell cultures. Cell viability and 11C-choline uptake in PDT-treated and control cells were measured. Results: For treated tumors, normalized 11C-choline uptake decreased significantly 24 and 48 h after PDT, compared with the same tumors before PDT (P < 0.001). For the control tumors, normalized 11C-choline uptake increased significantly. For mice with CWR22 tumors, the prostate-specific antigen level decreased 24 and 48 h after PDT. Pc 4-PDT in cell culture showed that the treated tumor cells, compared with the control cells, had less than 50% 11C-choline activity at 5, 30, and 45 min after PDT, whereas the cell viability test showed that the treated cells were viable longer than 7 h after PDT. Conclusion: PET with 11C- choline is sensitive for detecting early changes associated with Pc 4-PDT in mouse models of human prostate cancer. Choline PET has the potential to determine whether a PDT-treated tumor responds to treatment within 48 h after therapy.

AB - Photodynamic therapy (PDT) is a relatively new therapy that has shown promise for treating various cancers in both preclinical and clinical studies. The present study evaluated the potential use of PET with radiolabeled choline to monitor early tumor response to PDT in animal models. Methods: Two human prostate cancer models (PC-3 and CWR22) were studied in athymic nude mice. A second-generation photosensitizer, phthalocyanine 4 (Pc 4), was delivered to each animal by a tail vein injection 48 h before laser illumination. Small-animal PET images with 11C-choline were acquired before PDT and at 1, 24, and 48 h after PDT. Time-activity curves of 11C-choline uptake were analyzed before and after PDT. The percentage of the injected dose per gram of tissue was quantified for both treated and control tumors at each time point. In addition, Pc 4-PDT was performed in cell cultures. Cell viability and 11C-choline uptake in PDT-treated and control cells were measured. Results: For treated tumors, normalized 11C-choline uptake decreased significantly 24 and 48 h after PDT, compared with the same tumors before PDT (P < 0.001). For the control tumors, normalized 11C-choline uptake increased significantly. For mice with CWR22 tumors, the prostate-specific antigen level decreased 24 and 48 h after PDT. Pc 4-PDT in cell culture showed that the treated tumor cells, compared with the control cells, had less than 50% 11C-choline activity at 5, 30, and 45 min after PDT, whereas the cell viability test showed that the treated cells were viable longer than 7 h after PDT. Conclusion: PET with 11C- choline is sensitive for detecting early changes associated with Pc 4-PDT in mouse models of human prostate cancer. Choline PET has the potential to determine whether a PDT-treated tumor responds to treatment within 48 h after therapy.

KW - Choline molecular imaging

KW - Photodynamic therapy (PDT)

KW - Prostate cancer

KW - Small-animal PET

KW - Tumor response

UR - http://www.scopus.com/inward/record.url?scp=75149183221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149183221&partnerID=8YFLogxK

U2 - 10.2967/jnumed.109.067579

DO - 10.2967/jnumed.109.067579

M3 - Article

C2 - 20008981

AN - SCOPUS:75149183221

VL - 51

SP - 130

EP - 138

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 1

ER -